Juvederm and Restylane get most of the marketing attention in the dermal filler category. Sculptra is usually framed as the specialty, collagen-stimulating option for a narrower use case. The practice menu data tells a different story about which brand actually has the broadest footprint.
The filler mention counts
Across our census of 48,198 verified US aesthetic practices:
| Filler | Practices mentioning it |
|---|---|
| Sculptra | 4,174 |
| Restylane | 3,093 |
| Juvederm | 3,020 |
| Radiesse | 2,435 |
| Versa | 1,096 |
| RHA | 887 |
Sculptra leads the category, ahead of both Restylane and Juvederm, the two brands most people would name first if asked to guess the market leader.
Why this is counterintuitive
Sculptra has historically been positioned as a collagen biostimulator, a different mechanism and a different sales conversation than a hyaluronic acid filler like Juvederm or Restylane. It has a longer treatment protocol, typically multiple sessions, and a higher price point per course of treatment. None of that suggests it should have the widest practice adoption in the category.
But practice menus do not lie about what is actually being advertised. Sculptra's positioning as a longevity and skin-quality product, rather than a pure volumizer, appears to have broadened its adoption across practice types beyond where hyaluronic acid fillers dominate.
The rest of the field
Radiesse sits fourth at 2,435 mentions, another biostimulator-adjacent product with a similar longer-cycle sales story to Sculptra rather than the instant-result profile of a pure hyaluronic acid filler. The newer entrants, Versa at 1,096 and RHA at 887, are still a fraction of the top three brands' footprint. That gap is not necessarily a verdict on the products themselves. It reflects how much longer Sculptra, Restylane, and Juvederm have had to accumulate practice-level adoption, and how much harder it is for a newer brand to displace an established line item on a menu than to simply add itself as an option alongside it.
What it means that filler menus are getting more crowded
The average practice in our census that advertises fillers at all now lists more than one brand. That is consistent with the broader multi-device stacking pattern we see across the industry: practices are not picking a single filler and standardizing on it, they are offering a menu of options to match different patient goals, budgets, and prior brand loyalty. A patient who has always used Juvederm elsewhere is not a lost sale if the practice also carries it. A rep selling into an unstacked, single-brand practice is selling into a real gap, not just a preference.
What this means for a rep or manufacturer
If your territory plan assumes Juvederm or Restylane sets the ceiling for filler adoption in a market, the practice menu data says otherwise. A practice advertising Sculptra is a practice already comfortable with a premium, multi-session, consultative sale, which is a different buyer profile than a practice that only carries a single hyaluronic acid line.
For manufacturers selling adjacent devices or complementary treatments, a practice's filler mix is a signal worth scoring, not ignoring. A Sculptra-heavy menu suggests a practice built around results that take time and follow-up, which correlates with the kind of patient relationship that supports device-based treatments too.
Want this cut for your territory? Book a demo.